Is TransMedics Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22.
In comparison to peers, TransMedics has a P/E ratio of 50.23, which is more favorable than iRhythm Technologies, Inc. with a P/E of -111.60, but less favorable than Integer Holdings Corp. at 41.17. The company has shown strong performance with a year-to-date return of 88.66%, significantly outperforming the S&P 500's return of 13.30% over the same period, reinforcing its valuation narrative.